1
|
Huang Y, Jiang L, Liu J, Xu Y, Mo F, Su J, Tao R. Investigating a Causal Relationship Between Diabetes Mellitus and Oropharyngeal Cancer: A Mendelian Randomization Study. Community Dent Health 2023; 40:212-220. [PMID: 37988677 DOI: 10.1922/cdh_00025huang09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 02/03/2023] [Accepted: 05/01/2023] [Indexed: 11/23/2023]
Abstract
OBJECTIVE Previous observational studies reported an association of diabetes mellitus (DM) with oropharyngeal cancer (OPC), however, the potential causality of the association between them remains unclear. METHODS To explore this causal relationship in individuals of European descent, a two-sample Mendelian randomization (MR) study was conducted. A genome-wide association study (GWAS) of DM was used to represent the exposure factor (T1DM: n = 24,840; T2DM: n = 215,654), and GWAS of OPC represented the outcome (n = 3,448). RESULTS Forty-one single nucleotide polymorphisms (SNPs) related to T1DM and fifty-four SNPs related to T2DM were identified as effective instrumental variables (IVs) in the two-sample MR analyses. In IVW estimates, neither T1DM nor T2DM significantly contributed to an increased risk of OPC [T1DM: OR 1.0322 (95% CI 0.9718, 1.0963), P = 0.3033; T2DM: OR 0.9998 (95% CI 0.9995, 1.0002), P = 0.2858]. Four other regression models produced similar results. MR-Egger regression results [Cochran's Q statistic was 47.1544 (P = 0.1466) in T1DM, and 35.5084 (P = 0.9512) in T2DM] suggested no horizontal pleiotropy between IVs and outcomes. CONCLUSION Our findings suggest little evidence to support the genetic role of diabetes mellitus in OPC development in the European population.
Collapse
Affiliation(s)
- Y Huang
- Department of Periodontics and Oral medicine, College of Stomatology, Guangxi Medical University, China
| | - L Jiang
- Department of Periodontics and Oral medicine, College of Stomatology, Guangxi Medical University, China
| | - J Liu
- Department of Periodontics and Oral medicine, College of Stomatology, Guangxi Medical University, China
| | - Y Xu
- Department of Periodontics and Oral medicine, College of Stomatology, Guangxi Medical University, China
| | - F Mo
- Department of Periodontics and Oral medicine, College of Stomatology, Guangxi Medical University, China
| | - J Su
- Department of Periodontics and Oral medicine, College of Stomatology, Guangxi Medical University, China
| | - R Tao
- Department of Periodontics and Oral medicine, College of Stomatology, Guangxi Medical University, China
| |
Collapse
|
2
|
Liang Z, Xu G, Liu T, Zhong Y, Mo F, Li Z. Quantitatively biomechanical response analysis of posterior musculature reconstruction in cervical single-door laminoplasty. Comput Methods Programs Biomed 2023; 233:107479. [PMID: 36933316 DOI: 10.1016/j.cmpb.2023.107479] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Revised: 03/01/2023] [Accepted: 03/10/2023] [Indexed: 05/17/2023]
Abstract
BACKGROUND AND OBJECTIVE The current trend of laminoplasty is developing toward the goal of muscle preservation and minimum tissue damage. Given this, muscle-preserving techniques in cervical single-door laminoplasty have been modified with protecting the spinous processes at the sites of C2 and/or C7 muscle attachment and reconstruct the posterior musculature in recent years. To date, no study has reported the effect of preserving the posterior musculature during the reconstruction. The purpose of this study is to quantitatively evaluate the biomechanical effect of multiple modified single-door laminoplasty procedures for restoring stability and reducing response level on the cervical spine. METHODS Different cervical laminoplasty models were established for evaluating kinematics and response simulations based on a detailed finite element (FE) head-neck active model (HNAM), including ① C3 - C7 laminoplasty (LP_C37), ② C3 - C6 laminoplasty with C7 spinous process preservation (LP_C36), ③ C3 laminectomy hybrid decompression with C4 - C6 laminoplasty (LT_C3 + LP_C46) and ④ C3 - C7 laminoplasty with unilateral musculature preservation (LP_C37 + UMP). The laminoplasty model was validated by the global range of motion (ROM) and percentage changes relative to the intact state. The C2 - T1 ROM, axial muscle tensile force, and stress/strain levels of functional spinal units were compared among the different laminoplasty groups. The obtained effects were further analysed by comparison with a review of clinical data on cervical laminoplasty scenarios. RESULTS Analysis of the locations of concentration of muscle load showed that the C2 muscle attachment sustained more tensile loading than the C7 muscle attachment, primarily in flexion-extension (FE) and in lateral bending (LB) and axial rotation (AR), respectively. Simulated results further quantified that LP_C36 primarily produced 10% decreases in LB and AR modes relative to LP_C37. Compared with LP_C36, LT_C3 + LP_C46 resulted in approximately 30% decreases in FE motion; LP C37 + UMP also showed a similar trend. Additionally, when compared to LP_C37, LT_C3 + LP_C46 and LP C37 + UMP reduced the peak stress level at the intervertebral disc by at most 2-fold as well as the peak strain level of the facet joint capsule by 2-3-fold. All these findings were well correlated with the result of clinical studies comparing modified laminoplasty and classic laminoplasty. CONCLUSIONS Modified muscle-preserving laminoplasty is superior to classic laminoplasty due to the biomechanical effect of the posterior musculature reconstruction, with a retained postoperative ROM and loading response levels of the functional spinal units. More motion-sparing is beneficial for increasing cervical stability, which probably accelerates the recovery of postoperative neck movement and reduces the risk of the complication for eventual kyphosis and axial pain. Surgeons are encouraged to make every effort to preserve the attachment of the C2 whenever feasible in laminoplasty.
Collapse
Affiliation(s)
- Z Liang
- Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China; College of Mechanical and Vehicle Engineering, Hunan University, Changsha, Hunan 410082, China
| | - G Xu
- Department of Orthopedics, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Guangzhou University of Chinese Medicine, Shenzhen 518000, China
| | - T Liu
- Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
| | - Y Zhong
- Department of Spine Surgery, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, Guangxi 530023, China
| | - F Mo
- College of Mechanical and Vehicle Engineering, Hunan University, Changsha, Hunan 410082, China.
| | - Z Li
- Department of Spine Surgery, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, Guangxi 530023, China.
| |
Collapse
|
3
|
Yeo W, Yeo H, Lai K, Pang E, Mo F. P248 Evaluation of potential factors related to chemotherapy-induced nausea and vomiting (CINV) among Chinese breast cancer patients: individual patient data analysis. Breast 2023. [DOI: 10.1016/s0960-9776(23)00366-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/17/2023] Open
|
4
|
Chan S, Ryoo BY, Mo F, Cheon J, Li L, Wong K, Nicole Y, Kim H, Yoo C. LBA1 A phase II clinical trial to study the efficacy of cabozantinib in patients with hepatocellular carcinoma refractory to immune checkpoint inhibitor-based treatment. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
|
5
|
Zou Z, Pan M, Mo F, Jiang Q, Feng A, Zhou Y, Wang F, Liu X. High-fidelity ATP imaging via an isothermal cascade catalytic amplifier. Chem Sci 2022; 13:12198-12207. [PMID: 36349106 PMCID: PMC9601329 DOI: 10.1039/d2sc04560e] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2022] [Accepted: 09/29/2022] [Indexed: 09/19/2023] Open
Abstract
Artificial catalytic DNA circuits that can identify, transduce and amplify the biomolecule of interest have supplemented a powerful toolkit for visualizing various biomolecules in cancer cells. However, the non-specific response in normal tissues and the low abundance of analytes hamper their extensive biosensing and biomedicine applications. Herein, by combining tumor-responsive MnO2 nanoparticles with a specific stimuli-activated cascade DNA amplifier, we propose a multiply guaranteed and amplified ATP-sensing platform via the successive cancer-selective probe exposure and stimulation procedures. Initially, the GSH-degradable MnO2 nanocarrier, acting as a tumor-activating module, ensures the accurate delivery of the cascade DNA amplifier into GSH-rich cancer cells and simultaneously provides adequate Mn2+ cofactors for facilitating the DNAzyme biocatalysis. Then, the released cascade amplifier, acting as an ATP-monitoring module, fulfills the precise and sensitive analysis of low-abundance ATP in cancer cells where the catalyzed hairpin assembly (CHA) is integrated with the DNAzyme biocatalyst for higher signal gain. Additionally, the cascade catalytic amplifier achieved tumor-specific activated photodynamic therapy (PDT) after integrating an activatable photosensitizer into the system. This homogeneous cascade catalytic aptasensing circuit can detect low-abundance endogenous ATP of cancer cells, due to its intrinsically rich recognition repertoire and avalanche-mimicking hierarchical acceleration, thus demonstrating broad prospects for analyzing clinically important biomolecules and the associated physiological processes.
Collapse
Affiliation(s)
- Zhiqiao Zou
- College of Chemistry and Molecular Sciences, Wuhan University Wuhan 430072 P.R. China
| | - Min Pan
- Frontier Science Center for Immunology and Metabolism, Medical Research Institute, Wuhan University Wuhan 430072 P.R. China
| | - Fengye Mo
- College of Chemistry and Molecular Sciences, Wuhan University Wuhan 430072 P.R. China
| | - Qunying Jiang
- College of Chemistry and Molecular Sciences, Wuhan University Wuhan 430072 P.R. China
| | - Ailing Feng
- College of Chemistry and Molecular Sciences, Wuhan University Wuhan 430072 P.R. China
| | - Yizhuo Zhou
- College of Chemistry and Molecular Sciences, Wuhan University Wuhan 430072 P.R. China
| | - Fuan Wang
- College of Chemistry and Molecular Sciences, Wuhan University Wuhan 430072 P.R. China
| | - Xiaoqing Liu
- College of Chemistry and Molecular Sciences, Wuhan University Wuhan 430072 P.R. China
| |
Collapse
|
6
|
Xu Z, Shi T, Mo F, Yu W, Shen Y, Jiang Q, Wang F, Liu X. Programmable Assembly of Multivalent DNA‐Protein Superstructures for Tumor Imaging and Targeted Therapy. Angew Chem Int Ed Engl 2022. [DOI: 10.1002/ange.202211505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Zhen Xu
- Wuhan University College of Chemistry and Molecular Sciences 430072 Wuhan City CHINA
| | - Tianhui Shi
- Wuhan University College of Chemistry and Molecular Sciences 430072 Wuhan City CHINA
| | - Fengye Mo
- Wuhan University College of Chemistry and Molecular Sciences 430072 Wuhan City CHINA
| | - Wenqian Yu
- Wuhan University College of Chemistry and Molecular Sciences 430072 Wuhan City CHINA
| | - Yu Shen
- Wuhan University College of Chemistry and Molecular Sciences 430072 Wuhan City CHINA
| | - Qunying Jiang
- Wuhan University College of Chemistry and Molecular Sciences 430072 Wuhan City CHINA
| | - Fuan Wang
- Wuhan University College of Chemistry and Molecular Sciences 430072 Wuhan City CHINA
| | - Xiaoqing Liu
- Wuhan University College of Chemistry and Molecular Sciences No. 299 Bayi Road, Wuchang District 430072 Wuhan CHINA
| |
Collapse
|
7
|
Pellerino A, Bruno F, Mo F, Bertero L, Bellini E, Beano A, Montemurro F, Valiente M, Rudà R, Soffietti R. P11.26.A STAT3 expression in brain metastases from breast cancer: correlations with different molecular subtypes and clinical outcome. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac174.215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
STAT3 expression in peritumoral reactive astrocytes (RA) of brain metastases (BM) may favor a pro-metastatic environment. The aim of the study was to evaluate in a retrospective cohort of surgically resected BM from breast cancer (BC) the expression of pSTAT3 in RA of peritumoral tissue of BM, identify different patterns of expression according to molecular subtypes, and correlate with intracranial progression-free survival (i-PFS).
Material and Methods
Patients with histologically proven BM diagnosis from BC were identified from the biobank of Pathology Unit of University of Turin and Spanish national BrM network (RENACER). pSTAT3 expression was evaluated and scored in RA of peritumoral tissue using GFAP and STAT3 immunohistochemistry, according to Priego et al. (Nat Med 2018). Data on histological diagnosis, molecular subtypes, and i-PFS were retrieved by chart review. Intracranial progression was defined based on MRI reports.
Results
Eighty-five BM specimens from BC of 85 female patients with a median age of 54 years (range 30-81 years) were available for analysis. Immunohistochemistry for GFAP and pSTAT3 was feasible in 68/85 (80%). Fifteen out of 68 patients (21.1%) had BM from luminal BC, 27/68 (39.7%) from HER2-positive BC, and 26/68 (39.2%) from TNBC. Fifty-six out of 68 (82.4%) showed positive staining of pSTAT3 in peritumoral RA, of which 9/68 (13.3%) scored with 3, 26/68 (38.2%) with 2, and 21/68 (30.9%%) with 1, while pSTAT3 expression was negative (score 0) in 12/68 (17.6%). High pSTAT3 expression (score 2-3) was observed in 17/27 (62.9%) BM from HER2-positive BC and in 15/26 (57.7%) BM from TNBC, while most of BM from luminal BC (12/15 - 80%) had low or absent pSTAT3 (score 0-1) (p=0.021). Overall i-PFS was 16 months (range 7-41): low pSTAT3 BM (score 0-1) had a median i-PFS of 21 months versus 12 months for high pSTAT3 BM (score 2-3). A shorter median i-PFS was observed in high pSTAT3 BM from TNBC (4 months) as compared with low pSTAT3 BM (11 months). Conversely, i-PFS of high pSTAT3 BM (7 months) was similar to low pSTAT3 BM (6 months) in HER2-positive BC.
Conclusion
pSTAT3 expression in RA of peritumoral tissue of BM from TNBC and HER2-positive BC is higher than in BM from luminal BC. Of note, patients with high pSTAT3 BM from TNBC progressed earlier in comparison with those with low pSTAT3, suggesting that pSTAT3 expression has an influence on the outcome.
Collapse
Affiliation(s)
- A Pellerino
- Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science Hospital , Turin , Italy
| | - F Bruno
- Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science Hospital , Turin , Italy
| | - F Mo
- Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science Hospital , Turin , Italy
| | - L Bertero
- Pathology Unit, Department of Medical Sciences, University and City of Health and Science Hospital , Turin , Italy
| | - E Bellini
- Department of Medical Oncology 1, City of Health and Science Hospital , Turin , Italy
| | - A Beano
- Department of Medical Oncology 1, City of Health and Science Hospital , Turin , Italy
| | - F Montemurro
- Department of Medical Oncology, Institute for Cancer Research , Candiolo , Italy
| | - M Valiente
- Brain Metastasis Group, CNIO , Madrid , Spain
| | - R Rudà
- Department of Neurology, Castelfranco Veneto/Treviso Hospital , Treviso , Italy
- Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science Hospital , Turin , Italy
| | - R Soffietti
- Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science Hospital , Turin , Italy
| |
Collapse
|
8
|
Bruno F, Mo F, Meletti S, Belcastro V, Quadri S, Napolitano M, Bello L, Dainese F, Scarpelli M, Florindo I, Mascia A, Pauletto G, Pellerino A, Giovannini G, Polosa M, Sessa M, Conti Nibali M, Di Gennaro G, Gigli G, Cavallieri F, Pisanello A, Rudà R. OS02.6.A Lacosamide in monotherapy in brain tumour-related epilepsy (BTRE): results from an Italian multicentre retrospective study. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac174.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Lacosamide (LCM) is a third-generation anti-seizure medication (ASM) approved for focal onset epilepsy in patients aged ≥4 years. Previous studies have reported an efficacy of LCM as add-on treatment in brain tumour-related epilepsy (BTRE). To date, there are no studies in the literature focusing on lacosamide used in monotherapy to treat BTRE. In our retrospective study we investigated efficacy and tolerability of LCM in monotherapy in a multicentre national cohort of primary brain tumour patients.
Patients and Methods
Adult patients who were treated with LCM in monotherapy were collected from 12 Italian Centres (either mainly involved in neuro-oncology or in epileptology). Main inclusion criteria were diagnosis of primary brain tumour; at least two focal-onset seizures in the disease course; LCM used either as primary or secondary monotherapy after withdrawal of previous ASMs. For each patient, we evaluated seizure freedom at 3 and 6 months (primary endpoints), side effects and drop-out rate (secondary endpoints).
Results
We collected 132 patients. The majority of patients had a diagnosis of diffuse gliomas, being those with lower-grade glioma 66 (50.0%) and those with glioblastoma 33 (25.0%). Overall, LCM led to seizure-freedom in 64.4% of patients at 3 months and 55% at 6 months. Patients who used two or more ASMs before LCM had a worse seizure control than patients in monotherapy with LCM as first choice.In 14 patients, we observed seizure control despite tumour progression on magnetic resonance (MRI). Multivariate analysis showed that gross-total resection at diagnosis and use of steroids were significantly associated with higher seizure freedom rate at 6 months. Side effects were mainly mild (grade 1-2 according to the CTCAE classification), and the drop-out rate was low (1.5%). The main side effects were dizziness and somnolence.
Conclusion
This is the first study on the role of LCM in monotherapy in BTRE. The study has shown a good efficacy and tolerability of LCM with more than a half of patients becoming seizure-free at 6 months and with a very low rate of drop-out. Further studies are needed to confirm these preliminary data in a prospective manner, adding quality of life and neurocognitive functions as endpoints.
Collapse
Affiliation(s)
- F Bruno
- University and City of Health and Science, Turin, Italy , Turin , Italy
| | - F Mo
- University and City of Health and Science, Turin, Italy , Turin , Italy
| | - S Meletti
- Division of Neurology, Modena University Hospital, Modena, Italy , Modena , Italy
- Center for Neuroscience and Neurotechnology, Department of Biomedical, Metabolic and Neural Sciences; University of Modena and Reggio Emilia, Italy , Modena and Reggio Emilia , Italy
| | - V Belcastro
- Division of Neurology, Maggiore Hospital, Lodi, Italy , Lodi , Italy
| | - S Quadri
- Division of Neurology, ASST Papa Giovanni XXIII of Bergamo, Italy , Bergamo , Italy
| | - M Napolitano
- Division of Neurology and Stroke Unit, Hospital A. Cardarelli, Napoli, Italy , Naples , Italy
| | - L Bello
- Division of Neurosurgical Oncology, Department of Oncology and Hemato-oncology, Università degli Studi di Milano, Italy , Milan , Italy
| | - F Dainese
- Epilepsy Centre, Division of Neurology, Hospital of Venezia, Italy , Venice , Italy
| | - M Scarpelli
- Division of Neurology, Department of Neuroscience, AOUI Verona, Verona, Italy , Verona , Italy
| | - I Florindo
- Division of Neurology, Hospital of Parma, Italy , Parma , Italy
| | - A Mascia
- IRCCS Neuromed, Pozzilli, Italy , Pozzilli , Italy
| | - G Pauletto
- Neurology Unit, Department of Neuroscience, “S. Maria della Misericordia” University Hospital, Udine, Italy , Udine , Italy
| | - A Pellerino
- University and City of Health and Science, Turin, Italy , Turin , Italy
| | - G Giovannini
- Division of Neurology, Modena University Hospital, Modena, Italy , Modena , Italy
- Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy , Modena and Reggio Emilia , Italy
| | - M Polosa
- Division of Neurosurgery, ASST Lariana, Como, Italy , Como , Italy
| | - M Sessa
- Division of Neurology, ASST Papa Giovanni XXIII of Bergamo, Italy , Bergamo , Italy
| | - M Conti Nibali
- Division of Neurosurgical Oncology, Department of Oncology and Hemato-oncology, Università degli Studi di Milano, Italy , Milan , Italy
| | - G Di Gennaro
- IRCCS Neuromed, Pozzilli, Italy , Pozzilli , Italy
| | - G Gigli
- Department of Medicine (DAME), University of Udine, Udine, Italy , Udine , Italy
- Clinical Neurology Unit, “S. Maria della Misericordia” University Hospital, Udine, Italy , Udine , Italy
| | - F Cavallieri
- Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy , Modena and Reggio Emilia , Italy
- Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy , Reggio Emilia , Italy
| | - A Pisanello
- Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy , Reggio Emilia , Italy
| | - R Rudà
- University and City of Health and Science, Turin, Italy , Turin , Italy
- Dept. of Neurology, Castelfranco and Treviso Hospitals, Italy , Treviso , Italy
| |
Collapse
|
9
|
Shi YK, Zhou J, Zhao Y, Zhu B, Zhang L, Li X, Fang J, Shi J, Zhuang Z, Yang S, Wang D, Yu H, Zhang L, Zheng R, Greco M, Wang T, Mo F. 981P A phase IIa study to evaluate safety and efficacy of rezivertinib (BPI-7711) in locally advanced or metastatic/recurrent treatment-naïve NSCLC patients with EGFR mutation. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
10
|
Ho SSK, Hon SSF, Hung E, Lee JFY, Mo F, Tong M, So C, Chu S, Ng DCK, Lam D, Cho C, Mak TWC, Ng SSM, Futaba K, Suen J, To KF, Chan AWH, Yeung WWK, Ma BBY. Prognostic implication of the neoadjuvant rectal score and other biomarkers of clinical outcome in Hong Kong Chinese patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy. Hong Kong Med J 2022; 28:230-238. [PMID: 35667869 DOI: 10.12809/hkmj208969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
BACKGROUND Neoadjuvant chemoradiotherapy is a standard treatment for locally advanced rectal cancer, for which pathological complete response is typically used as a surrogate survival endpoint. Neoadjuvant rectal score is a new biomarker that has been shown to correlate with survival. The main objectives of this study were to investigate factors contributing to pathological complete response, to validate the prognostic significance of neoadjuvant rectal score, and to investigate factors associated with a lower neoadjuvant rectal score in a cohort of Hong Kong Chinese. METHODS Data of patients with locally advanced rectal cancer who received neoadjuvant chemoradiotherapy from August 2006 to October 2018 were retrieved from hospital records and retrospectively analysed. RESULTS Of 193 patients who had optimal response to neoadjuvant chemoradiotherapy and surgery, tumour down-staging was the only independent prognostic factor that predicted pathological complete response (P<0.0001). Neoadjuvant rectal score was associated with overall survival (hazard ratio [HR]=1.042, 95% confidence interval [CI]=1.021-1.064; P<0.0001), disease-free survival (HR=1.042, 95% CI=1.022-1.062; P<0.0001), locoregional recurrence-free survival (HR=1.070, 95% CI=1.039-1.102; P<0.0001) and distant recurrence-free survival (HR=1.034, 95% CI=1.012-1.056; P=0.002). Patients who had pathological complete response were associated with a lower neoadjuvant rectal score (P<0.0001), but pathological complete response was not associated with survival. For patients with intermediate neoadjuvant rectal scores, late recurrences beyond 72 months from diagnosis were observed. CONCLUSION Neoadjuvant rectal score is an independent prognostic marker of survival and disease recurrence in a cohort of Hong Kong Chinese patients who received neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
Collapse
Affiliation(s)
- S S K Ho
- Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong
| | - S S F Hon
- Department of Surgery, Alice Ho Miu Ling Nethersole Hospital, Hong Kong
| | - E Hung
- Department of Imaging and Interventional Radiology, Prince of Wales Hospital, Hong Kong
| | - J F Y Lee
- Department of Surgery, Prince of Wales Hospital, Hong Kong
| | - F Mo
- State Key Laboratory in Translational Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong
| | - M Tong
- State Key Laboratory in Translational Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong
| | - C So
- State Key Laboratory in Translational Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong
| | - S Chu
- Department of Surgery, Prince of Wales Hospital, Hong Kong
| | - D C K Ng
- Department of Surgery, North District Hospital, Hong Kong
| | - D Lam
- Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong
| | - C Cho
- Department of Imaging and Interventional Radiology, Prince of Wales Hospital, Hong Kong
| | - T W C Mak
- Department of Surgery, Prince of Wales Hospital, Hong Kong
| | - S S M Ng
- Department of Surgery, Prince of Wales Hospital, Hong Kong
| | - K Futaba
- Department of Surgery, Prince of Wales Hospital, Hong Kong
| | - J Suen
- Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong
| | - K F To
- Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong
| | - A W H Chan
- Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong
| | | | - B B Y Ma
- State Key Laboratory in Translational Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong
| |
Collapse
|
11
|
Luo D, Lin X, Zhao Y, Hu J, Mo F, Song G, Zou Z, Wang F, Liu X. A dynamic DNA nanosponge for triggered amplification of gene-photodynamic modulation. Chem Sci 2022; 13:5155-5163. [PMID: 35655573 PMCID: PMC9093187 DOI: 10.1039/d2sc00459c] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Accepted: 03/18/2022] [Indexed: 12/19/2022] Open
Abstract
Nucleic acid therapeutics has reached clinical utility through modulating gene expression. As a potential oligonucleotide drug, DNAzyme has RNA-cleaving activity for gene silencing, but faces challenges due to the lack of a safe and effective delivery vehicle and low in vivo catalytic activity. Here we describe DNAzyme-mediated gene regulation using dynamic DNA nanomaterials with intrinsic biocompatibility, stability, tumor-targeted delivery and uptake, and self-enhanced efficacy. We assemble programmable DNA nanosponges to package and deliver diverse nucleic acid drugs and therapeutic agents such as aptamer, DNAzyme and its cofactor precursor, and photosensitizer in one pot through the rolling circle amplification reaction, formulating a controllable nanomedicine using encoded instructions. Upon environmental stimuli, DNAzyme activity increases and RNA cleavage accelerates by a supplementary catalytic cofactor. In addition, this approach induces elevated O2 and 1O2 generation as auxiliary treatment, achieving simultaneously self-enhanced gene-photodynamic cancer therapy. These findings may advance the clinical trial of oligonucleotide drugs as tools for gene modulation. Oligonucleotide drug delivery approach is provided with a biomimetic, dynamic DNA nanomaterial, which enables disease gene regulation and auxiliary therapy in a controllable and self-boosting manner.![]()
Collapse
Affiliation(s)
- Dan Luo
- College of Chemistry and Molecular Sciences, Wuhan University 430072 Wuhan P. R. China
| | - Xue Lin
- College of Chemistry and Molecular Sciences, Wuhan University 430072 Wuhan P. R. China
| | - Yun Zhao
- College of Chemistry and Molecular Sciences, Wuhan University 430072 Wuhan P. R. China
| | - Jialing Hu
- College of Chemistry and Molecular Sciences, Wuhan University 430072 Wuhan P. R. China
| | - Fengye Mo
- College of Chemistry and Molecular Sciences, Wuhan University 430072 Wuhan P. R. China
| | - Gege Song
- College of Chemistry and Molecular Sciences, Wuhan University 430072 Wuhan P. R. China
| | - Zhiqiao Zou
- College of Chemistry and Molecular Sciences, Wuhan University 430072 Wuhan P. R. China
| | - Fuan Wang
- College of Chemistry and Molecular Sciences, Wuhan University 430072 Wuhan P. R. China
| | - Xiaoqing Liu
- College of Chemistry and Molecular Sciences, Wuhan University 430072 Wuhan P. R. China
| |
Collapse
|
12
|
Mo F, Meletti S, Belcastro V, Quadri S, Napolitano M, Bello L, Dainese F, Scarpelli M, Florindo I, Mascia A, Pauletto G, Bruno F, Pellerino A, Giovannini G, Polosa M, Sessa M, Conti Nibali M, Di Gennaro G, Gigli GL, Pisanello A, Cavallieri F, Rudà R. Lacosamide in monotherapy in BTRE (brain tumor-related epilepsy): results from an Italian multicenter retrospective study. J Neurooncol 2022; 157:551-559. [DOI: 10.1007/s11060-022-03998-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2022] [Accepted: 03/24/2022] [Indexed: 10/18/2022]
|
13
|
Cao Y, Mo F, Liu Y, Liu Y, Li G, Yu W, Liu X. Portable and sensitive detection of non-glucose target by enzyme-encapsulated metal-organic-framework using personal glucose meter. Biosens Bioelectron 2022; 198:113819. [PMID: 34836711 DOI: 10.1016/j.bios.2021.113819] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2021] [Revised: 10/16/2021] [Accepted: 11/16/2021] [Indexed: 11/02/2022]
Abstract
Personal glucose meter (PGM) is one of the most commercially available POC (point-of-care) devices for monitoring the level of glucose reliably, yet its non-glucose quantification ability is limited since such strategy needs ingenious interface design and tedious enzyme conjugation. Herein, we constructed a portable and sensitive platform that can detect non-glucose target by combining enzyme-encapsulated zeolitic imidazole framework-90 (ZIF-90) with personal glucose meter. ZIF-90 is an ideal carrier and susceptor due to the extraordinary capability of packaging enzyme and stimuli-responsiveness. We selected adenosine-5'-triphosphate (ATP) as the target model of non-glucose analytes. Upon ATP-induced decomposition of MOF, the released enzyme (glucose oxidase or invertase) catalyzed substrate and gave rise to the change of the glucose concentration for PGM assay. This method determined ATP with a remarkably sensitivity of 233 nM and effective recovery in real serum samples. Our strategy provides a facile and practical approach for measuring the non-glucose target using PGM, and could potentially be applied in bimolecular detection in point-of-care diagnosis.
Collapse
Affiliation(s)
- Yunzhe Cao
- College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, 430072, PR China
| | - Fengye Mo
- College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, 430072, PR China
| | - Yahua Liu
- College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, 430072, PR China; Animal, Plant and Foodstuffs Inspection Center of Tianjin Customs, Tianjin, 300461, PR China
| | - Yu Liu
- College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, 430072, PR China
| | - Gaiping Li
- College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, 430072, PR China; Department of Chemistry, Zhengzhou University, Zhengzhou, 450001, PR China
| | - Wenqian Yu
- College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, 430072, PR China
| | - Xiaoqing Liu
- College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, 430072, PR China.
| |
Collapse
|
14
|
Sun J, Liu F, Yu W, Fu D, Jiang Q, Mo F, Wang X, Shi T, Wang F, Pang D, Liu X. Visualization of Vaccine Dynamics with Quantum Dots for Immunotherapy. Angew Chem Int Ed Engl 2021; 60:24275-24283. [PMID: 34476884 PMCID: PMC8652846 DOI: 10.1002/anie.202111093] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Indexed: 01/02/2023]
Abstract
The direct visualization of vaccine fate is important to investigate its immunoactivation process to elucidate the detailed molecular reaction process at single-molecular level. Yet, visualization of the spatiotemporal trafficking of vaccines remains poorly explored. Here, we show that quantum dot (QD) nanomaterials allow for monitoring vaccine dynamics and for amplified immune response. Synthetic QDs enable efficient conjugation of antigen and adjuvants to target tissues and cells, and non-invasive imaging the trafficking dynamics to lymph nodes and cellular compartments. The nanoparticle vaccine elicits potent immune responses and anti-tumor efficacy alone or in combination with programmed cell death protein 1 blockade. The synthetic QDs showed high fluorescence quantum yield and superior photostability, and the reliable and long-term spatiotemporal tracking of vaccine dynamics was realized for the first time by using the synthetic QDs, providing a powerful strategy for studying immune response and evaluating vaccine efficacy.
Collapse
Affiliation(s)
- Junlin Sun
- College of Chemistry and Molecular SciencesWuhan UniversityWuhan430072P. R. China
| | - Feng Liu
- College of Chemistry and Molecular SciencesWuhan UniversityWuhan430072P. R. China
| | - Wenqian Yu
- College of Chemistry and Molecular SciencesWuhan UniversityWuhan430072P. R. China
| | - Dandan Fu
- College of Chemistry and Molecular SciencesWuhan UniversityWuhan430072P. R. China
| | - Qunying Jiang
- College of Chemistry and Molecular SciencesWuhan UniversityWuhan430072P. R. China
| | - Fengye Mo
- College of Chemistry and Molecular SciencesWuhan UniversityWuhan430072P. R. China
| | - Xiuyuan Wang
- College of Chemistry and Molecular SciencesWuhan UniversityWuhan430072P. R. China
| | - Tianhui Shi
- College of Chemistry and Molecular SciencesWuhan UniversityWuhan430072P. R. China
| | - Fuan Wang
- College of Chemistry and Molecular SciencesWuhan UniversityWuhan430072P. R. China
| | - Dai‐Wen Pang
- State Key Laboratory of Medicinal Chemical BiologyTianjin Key Laboratory of Biosensing and Molecular RecognitionFrontiers Science Center for New Organic MatterResearch Center for Analytical SciencesCollege of ChemistryFrontiers Science Center for Cell ResponsesNankai UniversityTianjin300071P. R. China
| | - Xiaoqing Liu
- College of Chemistry and Molecular SciencesWuhan UniversityWuhan430072P. R. China
| |
Collapse
|
15
|
Sun J, Liu F, Yu W, Fu D, Jiang Q, Mo F, Wang X, Shi T, Wang F, Pang D, Liu X. Visualization of Vaccine Dynamics with Quantum Dots for Immunotherapy. Angew Chem Int Ed Engl 2021. [DOI: 10.1002/ange.202111093] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Junlin Sun
- College of Chemistry and Molecular Sciences Wuhan University Wuhan 430072 P. R. China
| | - Feng Liu
- College of Chemistry and Molecular Sciences Wuhan University Wuhan 430072 P. R. China
| | - Wenqian Yu
- College of Chemistry and Molecular Sciences Wuhan University Wuhan 430072 P. R. China
| | - Dandan Fu
- College of Chemistry and Molecular Sciences Wuhan University Wuhan 430072 P. R. China
| | - Qunying Jiang
- College of Chemistry and Molecular Sciences Wuhan University Wuhan 430072 P. R. China
| | - Fengye Mo
- College of Chemistry and Molecular Sciences Wuhan University Wuhan 430072 P. R. China
| | - Xiuyuan Wang
- College of Chemistry and Molecular Sciences Wuhan University Wuhan 430072 P. R. China
| | - Tianhui Shi
- College of Chemistry and Molecular Sciences Wuhan University Wuhan 430072 P. R. China
| | - Fuan Wang
- College of Chemistry and Molecular Sciences Wuhan University Wuhan 430072 P. R. China
| | - Dai‐Wen Pang
- State Key Laboratory of Medicinal Chemical Biology Tianjin Key Laboratory of Biosensing and Molecular Recognition Frontiers Science Center for New Organic Matter Research Center for Analytical Sciences College of Chemistry Frontiers Science Center for Cell Responses Nankai University Tianjin 300071 P. R. China
| | - Xiaoqing Liu
- College of Chemistry and Molecular Sciences Wuhan University Wuhan 430072 P. R. China
| |
Collapse
|
16
|
Pellerino A, Palmiero R, Bruno F, Mo F, Muscolino E, Franchino F, Rudà R, Soffietti R. P14.42 Neratinib for treatment of leptomeningeal metastases from HER2-positive breast cancer in extended access program: preliminary results. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab180.159] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND
Leptomeningeal metastases (LM) occur in 5% of human epidermal growth factor receptor 2 (HER2) breast cancer (BC) with a poor overall survival (OS) of 3 months. Neratinib is an oral, irreversible tyrosine kinase pan-inhibitor that was approved by FDA for the treatment of HER2-enriched BC, who completed a prior adjuvant trastuzumab-based therapy. The aim of the study was to evaluate the activity of neratinib in LM from HER2-positive BC after the failure of multiple lines of treatment, including trastuzumab.
PATIENTS AND METHODS
Inclusion criteria were as follows: age ≥ 18 years; histological diagnosis of primary HER2-positive BC; newly-diagnosed LM according to LANO criteria; KPS ≥60 at the time of diagnosis of LM; coexistence of BM that have or not received WBRT or radiosurgery; systemic disease with a life expectancy of at least 3 months; concomitant drugs, including capecitabine, trastuzumab, TDM-1, pertuzumab, and hormone therapy were allowed, with the exclusion of lapatinib or other investigational agents. Neratinib was administered 240 mg daily continuously. The primary endpoint was the OS after the diagnosis of LM. Secondary endpoints were progression-free survival (PFS) following the diagnosis of LM, neurological benefit, radiological response rate, and tolerability.
RESULTS
From January 2018 to April 2021, 9 patients with LM have been enrolled. Median age at the time of diagnosis of LM was 44 years (95%CI 36–59) with a median KPS of 80 (95%CI 60–90). Median time since LM onset from the diagnosis of primary BC was 42 months (95%CI 11–166), and patients underwent a median number of adjuvant treatments before LM of 3 (95%CI 2–5). Three patients developed LM alone, and other 6 had LM associated with multiple brain metastases. Six-months and 1-year OS were 66.7% and 22.3%, respectively, with a median OS of 8 months (95%CI 3–13*). Median PFS was 3.5 months (95%CI 2–6) after the start of treatment. A neurological improvement was reported in 2/9 patients (22.2%), while in other 4/9 patients (44.5%) was achieved a neurological stabilization lasting for a median time of 5 months (95%CI 2–19). The best radiological response was a stable disease in 5/9 patients (55.6%), while no complete or partial response were achieved according to LANO and RANO criteria, respectively. A CSF clearance was observed in 1 patient only (11.1%) following two months of neratinib. Grade III-IV adverse events were not reported, and 2 patients only (22.2%) had mild diarrhea correlated with neratinib.
CONCLUSION
This is the first study that shows that neratinib might be a safe and effective treatment in LM from heavily pretreated HER2-positive BC.
Collapse
Affiliation(s)
- A Pellerino
- Department of Neuro-oncology, University and City of Health and Science Hospital, Turin, Italy
| | - R Palmiero
- Department of Neuro-oncology, University and City of Health and Science Hospital, Turin, Italy
| | - F Bruno
- Department of Neuro-oncology, University and City of Health and Science Hospital, Turin, Italy
| | - F Mo
- Department of Neuro-oncology, University and City of Health and Science Hospital, Turin, Italy
| | - E Muscolino
- Department of Neuro-oncology, University and City of Health and Science Hospital, Turin, Italy
| | - F Franchino
- Department of Neuro-oncology, University and City of Health and Science Hospital, Turin, Italy
| | - R Rudà
- Department of Neuro-oncology, University and City of Health and Science Hospital, Turin, Italy
- Department of Neurology, Castelfranco Veneto and Treviso Hospital, Treviso, Italy
| | - R Soffietti
- Department of Neuro-oncology, University and City of Health and Science Hospital, Turin, Italy
| |
Collapse
|
17
|
Liu Y, Mo F, Hu J, Jiang Q, Wang X, Zou Z, Zhang XZ, Pang DW, Liu X. Precision photothermal therapy and photoacoustic imaging by in situ activatable thermoplasmonics. Chem Sci 2021; 12:10097-10105. [PMID: 34349972 PMCID: PMC8317626 DOI: 10.1039/d1sc02203b] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2021] [Accepted: 06/24/2021] [Indexed: 01/06/2023] Open
Abstract
Phototherapy holds great promise for disease treatment; however, traditional "always-on" photoagents have been restricted to clinical translation due to their nonspecific response and side effects on normal tissues. Here, we show a tumor microenvironment activated photothermal and photoacoustic agent as an activatable prodrug and probe that allows precise cancer diagnosis and treatment. Such an in situ revitalized therapeutic and contrast agent is achieved via controllable plasmonic heating for thermoplasmonic activation. This enables monitoring of signal molecule dynamics, real-time photothermal and photoacoustic imaging of tumors and lymph node metastasis, and targeted photothermal therapy without unwanted phototoxicity to normal tissues. Our study provides a practical solution to the non-specificity problem in phototherapy and offers precision cancer therapeutic and theranostic strategies. This work may advance the development of ultrasensitive disease diagnosis and precision medicine.
Collapse
Affiliation(s)
- Yahua Liu
- College of Chemistry and Molecular Sciences, Wuhan University Wuhan 430072 P. R. China
| | - Fengye Mo
- College of Chemistry and Molecular Sciences, Wuhan University Wuhan 430072 P. R. China
| | - Jialing Hu
- College of Chemistry and Molecular Sciences, Wuhan University Wuhan 430072 P. R. China
| | - Qunying Jiang
- College of Chemistry and Molecular Sciences, Wuhan University Wuhan 430072 P. R. China
| | - Xiuyuan Wang
- College of Chemistry and Molecular Sciences, Wuhan University Wuhan 430072 P. R. China
| | - Zhiqiao Zou
- College of Chemistry and Molecular Sciences, Wuhan University Wuhan 430072 P. R. China
| | - Xian-Zheng Zhang
- College of Chemistry and Molecular Sciences, Wuhan University Wuhan 430072 P. R. China
| | - Dai-Wen Pang
- College of Chemistry and Molecular Sciences, Wuhan University Wuhan 430072 P. R. China
| | - Xiaoqing Liu
- College of Chemistry and Molecular Sciences, Wuhan University Wuhan 430072 P. R. China
| |
Collapse
|
18
|
Yeo W, Li L, Lau T, Lai K, Chan V, Wong K, Yip C, Pang E, Cheung M, Chan V, Kwok C, Suen J, Mo F. Evaluation of optimal prophylactic antiemetic regimens for doxorubicin-cyclophosphamide chemotherapy. Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)30869-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Liu F, Sun J, Yu W, Jiang Q, Pan M, Xu Z, Mo F, Liu X. Quantum dot-pulsed dendritic cell vaccines plus macrophage polarization for amplified cancer immunotherapy. Biomaterials 2020; 242:119928. [PMID: 32145508 DOI: 10.1016/j.biomaterials.2020.119928] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2019] [Revised: 02/22/2020] [Accepted: 02/26/2020] [Indexed: 12/14/2022]
Abstract
Dendritic cell (DC) vaccines hold great potential in cancer immunotherapy, but the suboptimal design of DC vaccines and the immunosuppressive tumor microenvironment largely impair their anti-tumor efficacy. Here, quantum dot (QD) pulsed-DC vaccines integrating with tumor-associated macrophage polarization are developed for amplified anti-tumor immunity. Semiconductor QDs are engineered with diverse functions to act as fluorescence nanoprobes, immunomodulatory adjuvants, and nanocarriers to load tumor antigens and Toll-like receptor 9 agonists. The QD-pulsed DC vaccines enable spatiotemporal tracking of lymphatic drainage and efficacy evaluation of DC immunotherapy, and trigger potent immunoactivation. Specifically, designer DC vaccine plus macrophage polarization elicits potent immune response to stimulate innate and adaptive antitumor immunity and ameliorate the immunosuppressive tumor microenvironment. As a new combination therapy, this strategy greatly boosts antigen-specific T-cell immunity and thus strongly inhibits local tumor growth and tumor metastasis in vivo. This study may provide an applicable treatment for cancer immunotherapy.
Collapse
Affiliation(s)
- Feng Liu
- Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, 430072, PR China
| | - Junlin Sun
- Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, 430072, PR China
| | - Wenqian Yu
- Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, 430072, PR China
| | - Qunying Jiang
- Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, 430072, PR China
| | - Min Pan
- Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, 430072, PR China
| | - Zhen Xu
- Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, 430072, PR China
| | - Fengye Mo
- Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, 430072, PR China
| | - Xiaoqing Liu
- Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, 430072, PR China.
| |
Collapse
|
20
|
Wang W, Liu Y, Shi T, Sun J, Mo F, Liu X. Biosynthesized Quantum Dot for Facile and Ultrasensitive Electrochemical and Electrochemiluminescence Immunoassay. Anal Chem 2019; 92:1598-1604. [PMID: 31808336 DOI: 10.1021/acs.analchem.9b04919] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Nanomaterials are commonly utilized for amplified immunoassay of biomarkers. However, traditional nanomaterial-based immunoassay usually requires a time-consuming and labor-intensive nanoparticle modification and conjugation process, which impedes their practical applications. Here, a new immunoassay method based on biosynthesized nanomaterials is developed with versatile functions for facile and ultrasensitive detection of cancer biomarker. In this method, the utilized biosynthesized quantum dots (BQDs) allow convenient antibody conjugation and electrode modification, and demonstrate excellent electrochemical and electrochemiluminescent responses. The differential pulse voltammetric, faradaic impedance spectroscopy, and electrochemiluminescent measurements with the BQD-modified electrode show detection limits at picomolar levels as well as good specificity toward human prostate-specific antigen detection. The inherent recognization capability as well as the inherent electrochemical and electrochemiluminescence features thus enable BQDs as good candidates for facile immunosensors with high sensitivity. Such a biosynthesized nanomaterial-based approach opens up the possibility of using innovative designs for nanoparticle-based assays, and developing reliable and practical methods for early disease diagnosis.
Collapse
Affiliation(s)
- Wenxiao Wang
- Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences , Wuhan University , Wuhan 430072 , P. R. China
| | - Yahua Liu
- Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences , Wuhan University , Wuhan 430072 , P. R. China
| | - Tianhui Shi
- Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences , Wuhan University , Wuhan 430072 , P. R. China
| | - Junlin Sun
- Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences , Wuhan University , Wuhan 430072 , P. R. China
| | - Fengye Mo
- Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences , Wuhan University , Wuhan 430072 , P. R. China
| | - Xiaoqing Liu
- Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences , Wuhan University , Wuhan 430072 , P. R. China
| |
Collapse
|
21
|
Lam G, Tong M, Lee J, Chu S, Ng D, Lam D, Cho C, Hung E, Li L, Ho W, Hui E, Chan A, Hon S, Mak T, Ng S, Suen J, Mo F, Ma B. A multicenter phase II study of neoadjuvant FOLFOXIRI followed by concurrent capecitabine and radiotherapy for high risk rectal cancer: A final report. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz421.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Pellerino A, Bello L, Conti Nibali M, Bruno F, Mo F, Pronello E, Franchino F, Soffietti R, Rudà R. P04.09 Patterns of care and impact on survival of first salvage therapy in high-risk grade II gliomas following initial temozolomide. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
BACKGROUND
Initial chemotherapy with temozolomide (TMZ) may provide benefit in high-risk low-grade gliomas. To date, no standard treatment is validated at first progression. The aim of this retrospective study was to investigate the optimal salvage therapy after the first progression and the factors that influence the PFS and overall survival (OS).
MATERIAL AND METHODS
we evaluated 71 patients with an histological diagnosis of grade II glioma according to WHO 2016 classification, who were included in a phase II AINO (Italian Association for Neuro-Oncology) trial, and progressed following initial chemotherapy with TMZ. Molecular data were available in all patients: 32 (45.1%) patients were oligodendrogliomas IDH 1/2 mutated and 1p19q codeleted, 11 (15.5%) were diffuse astrocytomas IDH mutant, and 28 (39.4%) were diffuse astrocytomas IDH wild-type. Thirty-five (49.3%) patients were MGMT methylated. Median follow up was 144 months (range 23–180).
RESULTS
thirty-one patients (43.7%) underwent second surgery, 24 patients (33.8%) second-line chemotherapy (rechallenge with TMZ or nitrosoureas), and 16 patients (22.5%) radiotherapy with a median PFS of 58 months (IC 95% 49–116). The association between prognostic factors and type of salvage therapy revealed a prevalence of younger age (≤ 45 years), non-enhancing tumor and location in eloquent area among patients treated with second surgery or chemotherapy, while aolder age (> 45 years) and contrast-enhancing tumors prevailed among patients receiving radiotherapy. Overall, median PFS was 60 months after second surgery (IC95% 43–116) and chemotherapy (IC95% 51–69), and 38 months after radiotherapy (IC95% 15–64) (p 0.09). No significant benefit in length of PFS was achieved in oligodendrogliomas undergoing second surgery (60 months) as compared with oligodendrogliomas treated with radiation or chemotherapy (58 months, p 0.11). PFS of diffuse astrocytomas IDH wild-type following second surgery (53 months) did not differ from that of patients treated with adjuvant treatments (65 months, p 0.28). Overall, median OS from the first salvage therapy was 117 months (IC95% 93 - 123+): 120 months (IC95% 108–140+) after second surgery, 94 months (IC95% 75–117+) after chemotherapy, and 62 months (IC95% 27–112) after radiotherapy (p 0.04). Median OS (123 months, IC95% 106–154) was prolonged in oligodendrogliomas receiving second surgery as compared to those receiving radiotherapy or chemotherapy (93 months, IC 95% 61–112, p 0.07), while median OS in diffuse astrocytomas IDH wild-type did not differ between those who received second surgery or radiotherapy or chemotherapy.
CONCLUSION: W
hen feasible, reoperation as first salvage treatment following initial TMZ in grade II gliomas seems to offer a probability of a longer OS as compared with second-line chemotherapy or radiotherapy, and this could hold true especially for oligodendrogliomas.
Collapse
Affiliation(s)
- A Pellerino
- Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - L Bello
- Department of Neurosurgery, Humanitas Hospital, Milan, Italy
| | - M Conti Nibali
- Department of Neurosurgery, Humanitas Hospital, Milan, Italy
| | - F Bruno
- Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - F Mo
- Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - E Pronello
- Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - F Franchino
- Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - R Soffietti
- Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - R Rudà
- Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| |
Collapse
|
23
|
Liu C, Wang L, Zhu R, Liu H, Ma R, Chen B, Li L, Guo Y, Jia Q, Shi S, Zhao D, Mo F, Zhao B, Niu J, Fu M, Orekhov AN, Brömme D, Gao S, Zhang D. Correction to: Rehmanniae Radix Preparata suppresses bone loss and increases bone strength through interfering with canonical Wnt/β-catenin signaling pathway in OVX rats. Osteoporos Int 2019; 30:1537-1540. [PMID: 31214751 DOI: 10.1007/s00198-019-05028-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
There was a mistake in the part of OVX rats model and RRP intervention in the original publication.
Collapse
Affiliation(s)
- C Liu
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
- Chinese Materia Medica School, Beijing University of Chinese Medicine, Beijing, 100029, China
| | - L Wang
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
- Chinese Materia Medica School, Beijing University of Chinese Medicine, Beijing, 100029, China
| | - R Zhu
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
| | - H Liu
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
| | - R Ma
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China
| | - B Chen
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
| | - L Li
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
| | - Y Guo
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
- The Third Affiliated Clinical Hospital, Beijing University of Chinese Medicine, Beijing, 100029, China
| | - Q Jia
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
| | - S Shi
- Chinese Materia Medica School, Beijing University of Chinese Medicine, Beijing, 100029, China
| | - D Zhao
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
| | - F Mo
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
| | - B Zhao
- Chinese Materia Medica School, Beijing University of Chinese Medicine, Beijing, 100029, China
| | - J Niu
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
| | - M Fu
- The Research Institute of McGill University Health Center, Montreal, Quebec, H4A 3J1, Canada
| | - A N Orekhov
- Laboratory of Angiopathology, Russian Academy of Medical Sciences, Institute of General Pathology and Pathophysiology, Moscow, 125315, Russia
| | - D Brömme
- Department of Oral Biological & Medical Sciences, Faculty of Dentistry, The University of British Columbia, Vancouver, BC, V6T 1Z3, Canada
| | - S Gao
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
| | - D Zhang
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China.
| |
Collapse
|
24
|
Liu C, Wang L, Zhu R, Liu H, Ma R, Chen B, Li L, Guo Y, Jia Q, Shi S, Zhao D, Mo F, Zhao B, Niu J, Fu M, Orekhov AN, Brömme D, Gao S, Zhang D. Rehmanniae Radix Preparata suppresses bone loss and increases bone strength through interfering with canonical Wnt/β-catenin signaling pathway in OVX rats. Osteoporos Int 2019; 30:491-505. [PMID: 30151623 DOI: 10.1007/s00198-018-4670-y] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2018] [Accepted: 08/13/2018] [Indexed: 12/17/2022]
Abstract
UNLABELLED Rehmanniae Radix Preparata (RRP) improves bone quality in OVX rats through the regulation of bone homeostasis via increasing osteoblastogenesis and decreasing osteoclastogenesis, suggesting it has a potential for the development of new anti-osteoporotic drugs. INTRODUCTION Determine the anti-osteoporotic effect of RRP in ovariectomized (OVX) rats and identify the signaling pathway involved in this process. METHODS OVX rats were treated with RRP aqueous extract for 14 weeks. The serum levels of tartrate-resistant acid phosphatase (TRAP), receptor activator of nuclear factor kappa-Β ligand (RANKL), alkaline phosphatase (ALP), and osteoprotegerin (OPG) were determined by ELISA. Bone histopathological alterations were evaluated by H&E, Alizarin red S, and Safranin O staining. Bone mineral density (BMD) and bone microstructure in rat femurs and lumbar bones were determined by dual-energy X-ray absorptiometry and micro-computed tomography. Femoral bone strength was detected by a three-point bending assay. The expression of Phospho-glycogen synthase kinase 3 beta (p-GSK-3β), GSK-3β, Dickkopf-related protein 1 (DKK1), cathepsin K, OPG, RANKL, IGF-1, Runx2, β-catenin, and p-β-catenin was determined by western blot and/or immunohistochemical staining. RESULTS Treatment of OVX rats with RRP aqueous extract rebuilt bone homeostasis demonstrated by increasing the levels of OPG as well as decreasing the levels of TRAP, RANKL, and ALP in serum. Furthermore, RRP treatment preserved BMD and mechanical strength by increasing cortical bone thickness and epiphyseal thickness as well as improving trabecular distribution in the femurs of OVX rats. In addition, RRP downregulated the expression of DKK1, sclerostin, RANKL, cathepsin K, and the ratio of p-β-catenin to β-catenin, along with upregulating the expression of IGF-1, β-catenin, and Runx2 and the ratio of p-GSK-3β to GSK-3β in the tibias and femurs of OVX rats. Echinacoside, jionoside A1/A2, acetoside, isoacetoside, jionoside B1, and jionoside B2 were identified in the RRP aqueous extract. CONCLUSION RRP attenuates bone loss and improves bone quality in OVX rats partly through its regulation of the canonical Wnt/β-catenin signaling pathway, suggesting that RRP has the potential to provide a new source of anti-osteoporotic drugs.
Collapse
Affiliation(s)
- C Liu
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
- Chinese Materia Medica School, Beijing University of Chinese Medicine, Beijing, 100029, China
| | - L Wang
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
- Chinese Materia Medica School, Beijing University of Chinese Medicine, Beijing, 100029, China
| | - R Zhu
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
| | - H Liu
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
| | - R Ma
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
- Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China
| | - B Chen
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
| | - L Li
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
| | - Y Guo
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
- The Third Affiliated Clinical Hospital, Beijing University of Chinese Medicine, Beijing, 100029, China
| | - Q Jia
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
| | - S Shi
- Chinese Materia Medica School, Beijing University of Chinese Medicine, Beijing, 100029, China
| | - D Zhao
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
| | - F Mo
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
| | - B Zhao
- Chinese Materia Medica School, Beijing University of Chinese Medicine, Beijing, 100029, China
| | - J Niu
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
| | - M Fu
- The Research Institute of McGill University Health Center, Montreal, Quebec, H4A 3J1, Canada
| | - A N Orekhov
- Laboratory of Angiopathology, Russian Academy of Medical Sciences, Institute of General Pathology and Pathophysiology, Moscow, 125315, Russia
| | - D Brömme
- Department of Oral Biological & Medical Sciences, Faculty of Dentistry, The University of British Columbia, Vancouver, BC, V6T 1Z3, Canada
| | - S Gao
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China
| | - D Zhang
- Diabetes Research Center, Traditional Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China.
| |
Collapse
|
25
|
Ma B, van der Velden N, Mo F, Loong H, Siu L, Goh B, Bang YJ, Lin CC, Desai J, Lolkema M. Phase I investigator’s perceptions to ‘supersized seamless trials in oncology'. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy430.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
26
|
Poon D, Lam D, Wong K, Mok F, Mo F, Chu C, Ng A, Suen J, Chan A. Stereotactic body radiotherapy (SBRT) versus conventional fractionated intensity-modulated radiotherapy (CF-IMRT) for Asian patients with early-stage localized prostate cancer: Acute toxicity results from a prospective randomized phase II study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy434.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Chan O, Lam K, Li J, Choi F, Wong C, Chang A, Mo F, Wang K, Yeung R, Mok T. OA07.02 ATOM: A Phase II Study to Assess Efficacy of Preemptive Local Ablative Therapy to Residual Oligometastases After EGFR TKI. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
28
|
Pellerino A, Rudà R, Franchino F, Marchese G, Bruno F, Mo F, Soffietti R. P05.47 Long-lasting response in spinal metastases from ALK rearranged Non-Small-Cell Lung Cancer treated with different ALK inhibitors. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- A Pellerino
- Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - R Rudà
- Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - F Franchino
- Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - G Marchese
- Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - F Bruno
- Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - F Mo
- Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| | - R Soffietti
- Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy
| |
Collapse
|
29
|
Ma B, King AD, Leung L, Wang K, Poon A, Ho WM, Mo F, Chan CML, Chan ATC, Wong SCC. Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer-a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria. Ann Oncol 2018; 28:1576-1581. [PMID: 28379285 DOI: 10.1093/annonc/mdx149] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2016] [Indexed: 12/20/2022] Open
Abstract
Background This study investigated the predictive and prognostic significance of assessing early drug response with both positron-emission computerized tomography (PET-CT) and circulating tumor cells (CTCs) in patients receiving first-line chemotherapy for metastatic colorectal cancer. Patients and methods Eligible patients had PET-CT and CTC analysis at baseline and 4-6 weeks after starting chemotherapy, and then a CT scan at 10-12 weeks to assess the Response Evaluation Criteria In Solid Tumors (RECIST) response. Early response was defined as achieving a dual-endpoint consisting of PET-CT (30% drop in the sum of maximum standard uptake values-SUVmax-of target lesions) and CTC response (CTC < 3 cells/7.5 ml blood) at 4-6 weeks after starting chemotherapy. Results About 84 patients were enrolled with a median follow-up of 32.9 months (95% confidence interval, CI, 24.5 months-not reached, NR), and 70 patients (84.3%) completed all assessments. Achieving an early response based on the dual-endpoint was independently associated with progression-free survival (hazard ratio, HR = 0.452, 95% CI 0.267-0.765). The median progression-free survival of early responders was 7.41 months (95% CI, 6.05-9.11) compared with 5.37 months (95% CI, 4.68-6.24) in non-responders (log-rank, P = 0.0167). RECIST response at 10 weeks was independently associated with overall survival (OS) (HR = 0.484, 95% CI, 0.275-0.852). Early response based on the dual-endpoint could predict the subsequent RECIST response with a sensitivity, specificity and positive predictive value of 64%, 70% and 74%, respectively. Conclusions Early response based on both PET-CT and CTC analysis has prognostic and probably predictive significance in patients undergoing first-line chemotherapy for metastatic colorectal cancer. Its utility as a new tool for assessing early drug response should be further validated.
Collapse
Affiliation(s)
- B Ma
- State Key Laboratory of Oncology in South China, Department of Clinical Oncology, Sir Y K Pao Centre for Cancer, Hong Kong Cancer Institute
| | - A D King
- Department of Diagnostic and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR
| | - L Leung
- State Key Laboratory of Oncology in South China, Department of Clinical Oncology, Sir Y K Pao Centre for Cancer, Hong Kong Cancer Institute
| | - K Wang
- Department of Diagnostic and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR
| | - A Poon
- State Key Laboratory of Oncology in South China, Department of Clinical Oncology, Sir Y K Pao Centre for Cancer, Hong Kong Cancer Institute
| | - W M Ho
- State Key Laboratory of Oncology in South China, Department of Clinical Oncology, Sir Y K Pao Centre for Cancer, Hong Kong Cancer Institute
| | - F Mo
- State Key Laboratory of Oncology in South China, Department of Clinical Oncology, Sir Y K Pao Centre for Cancer, Hong Kong Cancer Institute
| | - C M L Chan
- State Key Laboratory of Oncology in South China, Department of Clinical Oncology, Sir Y K Pao Centre for Cancer, Hong Kong Cancer Institute
| | - A T C Chan
- State Key Laboratory of Oncology in South China, Department of Clinical Oncology, Sir Y K Pao Centre for Cancer, Hong Kong Cancer Institute
| | - S C C Wong
- Department of Health Technology and Informatics, Faculty of Health and Social Sciences, Hong Kong Polytechnic University, Hong Kong SAR, China
| |
Collapse
|
30
|
Hui E, Chan A, Ngan R, Tung S, Cheng A, Ng W, Lee V, Ma B, Cheng H, Wong F, Loong H, Tong M, Poon D, Ahuja A, King A, Wang K, Mo F, Zee B, Chan K, Lo Y. Biomarker analysis of randomized controlled trial (RCT) of adjuvant chemotherapy (CT) using plasma EBV DNA to identify patients (pts) at higher risk of relapse after radiotherapy (RT) or chemoradiation (CRT) in nasopharyngeal cancer (NPC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Loong H, Yuen C, Mo F, Chan TC, Lee K, Chan A, Wong A, Wong K, Lam CM, Tong J, Wong C, Yeo W. Pembrolizumab in patients with advanced/metastatic acral lentiginous melanoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx667.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Campion D, Dakhil N, Llari M, Evin M, Mo F, Thefenne L, Behr M. Finite element model of a below-knee amputation: a feasibility study. Comput Methods Biomech Biomed Engin 2017; 20:35-36. [PMID: 29088638 DOI: 10.1080/10255842.2017.1382848] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- D Campion
- a Laboratoire de Biomécanique Appliquée
| | - N Dakhil
- a Laboratoire de Biomécanique Appliquée
| | - M Llari
- a Laboratoire de Biomécanique Appliquée
| | - M Evin
- a Laboratoire de Biomécanique Appliquée
| | - F Mo
- b College of Vehicle and Mechanical Engineering , Hunan University , China
| | - L Thefenne
- c Hôpital d'Instruction des armées de Laveran
| | - M Behr
- a Laboratoire de Biomécanique Appliquée
| |
Collapse
|
33
|
Loong H, Mo F, Li L, Lee C, Lam KC, Koh J, Chiu P, Teoh A, Chan A, Ng E, Yeo W. A Phase I/II study everolimus in combination with paclitaxel-carboplatin in patients with advanced adenocarcinoma of the stomach. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx367.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Chan OSH, Lee VHF, Mok TSK, Mo F, Chang ATY, Yeung RMW. The Role of Radiotherapy in Epidermal Growth Factor Receptor Mutation-positive Patients with Oligoprogression: A Matched-cohort Analysis. Clin Oncol (R Coll Radiol) 2017; 29:568-575. [PMID: 28499791 DOI: 10.1016/j.clon.2017.04.035] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2017] [Revised: 03/23/2017] [Accepted: 04/06/2017] [Indexed: 11/26/2022]
Abstract
AIMS Almost all patients with epidermal growth factor receptor (EGFR) mutations will develop resistance to first-line EGFR tyrosine kinase inhibitors (TKIs). The management of oligoprogression on EGFR TKI is controversial. Irradiating progressing tumours may potentially eradicate the resistant clone and allow continuation of EGFR TKI, but the clinical data remain sparse. We aimed to assess the effect of radiotherapy on survival outcomes in patients with oligoprogression in a matched-cohort study. MATERIALS AND METHODS This was a retrospective matched-cohort study comparing patients with EGFR mutation-positive stage IV non-small cell lung cancer receiving radiotherapy versus chemotherapy for progression. Patients in the radiotherapy group received radiotherapy (mainly stereotactic ablative radiotherapy) for oligoprogression, whereas the chemotherapy group received only systemic chemotherapy upon progression. Key prognostic factors including gender, age, performance status, time to first progression and mutation subtypes were matched. RESULTS Twenty-five patients with oligoprogression (radiotherapy group) were identified, and a matched chemotherapy group with the same number of patients was generated. The median duration of follow-up was 24.3 and 34 months for the radiotherapy and chemotherapy groups, respectively. The median overall survival of the radiotherapy group was significantly longer than the chemotherapy group, 28.2 versus 14.7 months (P = 0.026). The median progression-free survival (PFS) was 7.0 and 4.1 months after radiotherapy and chemotherapy, respectively (P = 0.0017). The use of radiotherapy was an independent predictive factor of overall survival and PFS in multivariate analysis. Only one patient had ≥grade 3 toxicity after radiotherapy. The frequency of secondary T790M mutation and subsequent Osimertinib exposure were similar in both groups. CONCLUSION Radiotherapy may effectively extend EGFR TKI therapy for patients with oligoprogression on TKI. Improved PFS and overall survival were observed, although potential biases should not be overlooked. Further randomised studies are warranted.
Collapse
Affiliation(s)
- O S H Chan
- Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China.
| | - V H F Lee
- Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, China
| | - T S K Mok
- Department of Clinical Oncology, Faculty of Medicine, The Chinese University of Hong Kong, China
| | - F Mo
- Department of Clinical Oncology, Faculty of Medicine, The Chinese University of Hong Kong, China
| | - A T Y Chang
- Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China; Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, China
| | - R M W Yeung
- Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China
| |
Collapse
|
35
|
Yeo W, Mo F, Pang E, Suen J, Lee K, Ho W, Chan V, Koh J, Liem G. Quality of life of premenopausal Chinese breast cancer patients after adjuvant chemotherapy. Breast 2017. [DOI: 10.1016/s0960-9776(17)30119-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
36
|
Hui E, Ma B, Mo F, Kam M, Chan S, Loong H, Ho R, Leung S, King A, Wang K, Ahuja A, Chan C, Hui C, Wong C, Chan A. Axitinib in recurrent or metastatic nasopharyngeal carcinoma (NPC): final result of a phase 2 clinical trial with pharmacokinetic (PK) correlation. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw376.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Steensma C, Loukine L, Orpana H, McRae L, Vachon J, Mo F, Boileau-Falardeau M, Reid C, Choi BC. Describing the population health burden of depression: health-adjusted life expectancy by depression status in Canada. Health Promot Chronic Dis Prev Can 2016; 36:205-213. [PMID: 27768557 PMCID: PMC5158123 DOI: 10.24095/hpcdp.36.10.01] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
INTRODUCTION Few studies have evaluated the impact of depression in terms of losses to both premature mortality and health-related quality of life (HRQOL) on the overall population. Health-adjusted life expectancy (HALE) is a summary measure of population health that combines both morbidity and mortality into a single summary statistic that describes the current health status of a population. METHODS We estimated HALE for the Canadian adult population according to depression status. National Population Health Survey (NPHS) participants 20 years and older (n = 12 373) were followed for mortality outcomes from 1994 to 2009, based on depression status. Depression was defined as having likely experienced a major depressive episode in the previous year as measured by the Composite International Diagnostic Interview Short Form. Life expectancy was estimated by building period abridged life tables by sex and depression status using the relative risks of mortality from the NPHS and mortality data from the Canadian Chronic Disease Surveillance System (2007-2009). The Canadian Community Health Survey (2009/10) provided estimates of depression prevalence and Health Utilities Index as a measure of HRQOL. Using the combined mortality, depression prevalence and HRQOL estimates, HALE was estimated for the adult population according to depression status and by sex. RESULTS For the population of women with a recent major depressive episode, HALE at 20 years of age was 42.0 years (95% CI: 40.2-43.8) compared to 57.0 years (95% CI: 56.8-57.2) for women without a recent major depressive episode. For the population of Canadian men, HALE at 20 was 39.0 years (95% CI: 36.5-41.5) for those with a recent major depressive episode compared to 53.8 years (95% CI: 53.6-54.0) for those without. For the 15.0-year difference in HALE between women with and without depression, 12.3 years can be attributed to the HRQOL gap and the remaining 2.7 years to the mortality gap. The 14.8 fewer years of HALE observed for men with depression equated to a 13.0-year HRQOL gap and a 1.8-year mortality gap. CONCLUSION The population of adult men and women with depression in Canada had substantially lower healthy life expectancy than those without depression. Much of this gap is explained by lower levels of HRQOL, but premature mortality also plays a role.
Collapse
Affiliation(s)
- C Steensma
- Health Promotion and Chronic Disease Prevention Branch, Public Health Agency of Canada, Government of Canada, Ottawa, Ontario, Canada
- Department of Social and Preventive Medicine, Université de Montréal, Montréal, Quebec, Canada
| | - L Loukine
- Health Promotion and Chronic Disease Prevention Branch, Public Health Agency of Canada, Government of Canada, Ottawa, Ontario, Canada
| | - H Orpana
- Health Promotion and Chronic Disease Prevention Branch, Public Health Agency of Canada, Government of Canada, Ottawa, Ontario, Canada
- School of Psychology, University of Ottawa, Ottawa, Ontario, Canada
| | - L McRae
- Health Promotion and Chronic Disease Prevention Branch, Public Health Agency of Canada, Government of Canada, Ottawa, Ontario, Canada
| | - J Vachon
- Health Promotion and Chronic Disease Prevention Branch, Public Health Agency of Canada, Government of Canada, Ottawa, Ontario, Canada
| | - F Mo
- Health Promotion and Chronic Disease Prevention Branch, Public Health Agency of Canada, Government of Canada, Ottawa, Ontario, Canada
| | - M Boileau-Falardeau
- Health Promotion and Chronic Disease Prevention Branch, Public Health Agency of Canada, Government of Canada, Ottawa, Ontario, Canada
- Department of Social and Preventive Medicine, Université de Montréal, Montréal, Quebec, Canada
| | - C Reid
- Health Promotion and Chronic Disease Prevention Branch, Public Health Agency of Canada, Government of Canada, Ottawa, Ontario, Canada
| | - B C Choi
- Health Promotion and Chronic Disease Prevention Branch, Public Health Agency of Canada, Government of Canada, Ottawa, Ontario, Canada
- Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
- Injury Prevention Research Center, Shantou University Medical College, Shantou, China
| |
Collapse
|
38
|
Yeo W, Mo F, Suen J, Loong H, Pang E, Yip C, Liem G. Dyslipidaemias after adjuvant chemotherapy in young Chinese breast cancer patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw364.57] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Zhang Y, Xiao F, Lu S, Song J, Zhang C, Li J, Gu K, Lan A, Lv B, Zhang R, Mo F, Jiang G, Zhang X, Yang X. Research trends and perspectives of male infertility: a bibliometric analysis of 20 years of scientific literature. Andrology 2016; 4:990-1001. [PMID: 27389996 DOI: 10.1111/andr.12204] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2016] [Revised: 03/25/2016] [Accepted: 03/31/2016] [Indexed: 12/14/2022]
Affiliation(s)
- Y. Zhang
- Medical Scientific Research Center; Guangxi Medical University; Nanning Guangxi China
| | - F. Xiao
- Medical Scientific Research Center; Guangxi Medical University; Nanning Guangxi China
| | - S. Lu
- Center for Reproductive Medicine; Provincial Hospital Affiliated to Shandong University; Jinan China
| | - J. Song
- The Second Affiliated Hospital of Guilin Medical University; Guilin Guangxi China
| | - C. Zhang
- Medical Scientific Research Center; Guangxi Medical University; Nanning Guangxi China
| | - J. Li
- Medical Scientific Research Center; Guangxi Medical University; Nanning Guangxi China
| | - K. Gu
- Department of Urology; The First Affiliated Hospital of Guangxi Medical University; Nanning Guangxi China
| | - A. Lan
- Medical Scientific Research Center; Guangxi Medical University; Nanning Guangxi China
| | - B. Lv
- Department of Urology; The First Affiliated Hospital of Guangxi Medical University; Nanning Guangxi China
| | - R. Zhang
- Medical Scientific Research Center; Guangxi Medical University; Nanning Guangxi China
| | - F. Mo
- Beijing University of Chinese Medicine; Beijing China
| | - G. Jiang
- Beijing University of Chinese Medicine; Beijing China
| | - X. Zhang
- Department of Urology; Zhongnan Hospital of Wuhan University; Wuhan Hubei China
| | - X. Yang
- Medical Scientific Research Center; Guangxi Medical University; Nanning Guangxi China
| |
Collapse
|
40
|
Ma B, Leung S, Hui E, King A, Wang K, Mo F, Li L, Loong H, Kam M, Chan A, Wong S, Chan A. 2870 Prospective evaluation of both plasma Epstein Barr Virus (EBV) DNA clearance and fludeoxyglucose-positron emission tomography (PET-CT) as a dual-endpoint in predicting early response and survival of patients undergoing chemotherapy (chemo) for advanced nasopharyngeal carcinoma (NPC) (NCT01365208). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31608-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
41
|
Chan S, Mo F, Chan A, Chan C, Mok K, Liu C, Tang N, Chan A, Yeo W. P-108 Systematic evaluation of serum inflammatory markers for prognostication of hepatocellular carcinoma (HCC). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Chan S, Yeo W, Mo F, Li L, Lee K, Hui P, Ma B, Mok T, Chan A, Lai P, Yu S. A Phase Ii Study on Combination of Axitinib and Transarterial Chemoembolization (Tace) for Treatment of Inoperable Hepatocellular Carcinoma (Hcc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.115] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
43
|
Leung SF, Chan KCA, Ma BB, Hui EP, Mo F, Chow KCK, Leung L, Chu KW, Zee B, Lo YMD, Chan ATC. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol 2014; 25:1204-8. [PMID: 24638904 DOI: 10.1093/annonc/mdu117] [Citation(s) in RCA: 148] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND To test the hypothesis that prognostication of treatment outcome is feasible by biomarker response at midcourse of chemoradiotherapy (CRT)/radiotherapy (RT), with respect to the plasma load of Epstein-Barr viral (EBV) DNA in nasopharyngeal carcinoma (NPC). PATIENTS AND METHODS One hundred seven patients with stage IIB-IV NPC were prospectively studied. Plasma EBV DNA load was measured by quantitative PCR before therapy (pre-DNA), at completion of 4 weeks of CRT/RT (mid-DNA), and within 3 months of completion of therapy (post-DNA). The end points are post-DNA load, a recognized surrogate of survival, and clinical outcome. RESULTS Ninety-three percent of patients had detectable EBV DNA before therapy (median load = 972 copies/ml). EBV DNA became undetectable in 55 (51%) patients at the end of week 4 of therapy. Detectable mid-DNA was associated with worse clinical outcome (median follow-up time, 6.2 years), for distant failure [hazard ratio (HR) 12.02, 95% confidence interval (CI) 2.78-51.93; P < 0.0001], progression-free survival (PFS; HR 4.05, 95% CI 1.89-8.67, P < 0.0001), and overall survival (OS; HR 3.29, 95% CI 1.37-7.90, P = 0.0077). Seventy-four percent of all failures were associated with detectable mid-DNA, whereas 34% of all failures were associated with detectable post-DNA. Stratification by tumor stage (IIB, III, IV) has no significant prognostic effect. CONCLUSIONS Unfavorable EBV DNA response at midcourse of RT/CRT is an adverse prognosticator for treatment outcome, is linked to majority of all failures, and discriminates outcome better than tumor stage. The data could provide a basis for trial design that addresses alteration of therapy intensity during the latter phase of CRT, and adjuvant therapy. Validation studies are awaited.
Collapse
Affiliation(s)
| | | | - B B Ma
- Department of Clinical Oncology
| | - E P Hui
- Department of Clinical Oncology
| | - F Mo
- Department of Clinical Oncology
| | | | - L Leung
- Department of Clinical Oncology
| | - K W Chu
- Department of Clinical Oncology
| | - B Zee
- Department of School of Public Health, State Key Laboratory in Oncology in South China, Sir YK Pao Center for Cancer, The Chinese University of Hong Kong, Shatin, Hong Kong
| | - Y M D Lo
- Department of Chemical Pathology
| | | |
Collapse
|
44
|
Huchcroft SA, McGowan CR, Mo F. Injuries related to consumer products in Canada--a systematic literature review. Chronic Dis Inj Can 2013; 33:175-187. [PMID: 23735457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
OBJECTIVES To conduct a systematic literature review of injury related to certain consumer products. METHODS Forty-six empirical research reports along with 32 surveillance reports from the Canadian Hospitals Injury Reporting and Prevention Program (CHIRPP) were examined to determine the approximate number of injuries associated with a given product per year and any trends in frequency. Percentages of injuries that: (1) resulted in hospitalization, (2) appeared to result from the product itself and (3) were associated with risky or inappropriate use and/or non-use of a helmet were also extracted from the reports. RESULTS Outdoor play and sports equipment appear to be associated with the greatest numbers of injuries. A relatively high proportion of injuries appear to result from inappropriate or risky use of a product and/or inadequate safety precautions. CONCLUSION This review identified the following areas of concern regarding consumer products and injuries: lack of helmet use by people using in-line skates, sleds, snowboards, downhill skis and personal-powered watercraft; operation of all-terrain vehicles (ATVs) and snowmobiles by alcohol-impaired people; operation of snowmobiles at excessive speeds; poor design of playground equipment; and unsafe storage and use of matches.
Collapse
Affiliation(s)
- S A Huchcroft
- Department of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, United Kingdom
| | | | | |
Collapse
|
45
|
Abstract
Objectives
To conduct a systematic literature review of injury related to certain consumer products.
Methods
Forty-six empirical research reports along with 32 surveillance reports from the Canadian Hospitals Injury Reporting and Prevention Program (CHIRPP) were examined to determine the approximate number of injuries associated with a given product per year and any trends in frequency. Percentages of injuries that: (1) resulted in hospitalization, (2) appeared to result from the product itself and (3) were associated with risky or inappropriate use and/or non-use of a helmet were also extracted from the reports.
Results
Outdoor play and sports equipment appear to be associated with the greatest numbers of injuries. A relatively high proportion of injuries appear to result from inappropriate or risky use of a product and/or inadequate safety precautions.
Conclusion
This review identified the following areas of concern regarding consumer products and injuries: lack of helmet use by people using in-line skates, sleds, snowboards, downhill skis and personal-powered watercraft; operation of all-terrain vehicles (ATVs) and snowmobiles by alcohol-impaired people; operation of snowmobiles at excessive speeds; poor design of playground equipment; and unsafe storage and use of matches.
Collapse
Affiliation(s)
- SA Huchcroft
- Epidemiology Consultant, Calgary, Alberta, Canada
| | - CR McGowan
- Department of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, United Kingdom
| | - F Mo
- Science Integration Division, Centre for Chronic Disease Prevention and Control, Public Health Agency of Canada, Ottawa, Ontario, Canada
| |
Collapse
|
46
|
Abstract
Introduction
To understand the distribution pattern and time trend of unintentional injury mortalities is crucial in order to develop prevention strategies.
Methods
We analyzed vital statistics data from Canada (excluding Quebec) for 2001 to 2007. Mortality rates were age- and sex-standardized to the 2001 Canadian population. An autoregressive model was used for time-series analysis.
Results
Overall mortality rate steadily decreased but unintentional injury mortality rate was stable over the study period. The three territories had the highest mortality rates. Unintentional injury deaths were less common in children than in youths/adults. After 60, the mortality rate increased steadily with age. Males were more likely to die of unintentional injury, and the male/female ratio peaked in the 25- to 29-year age group. Motor vehicle crashes, falls and poisoning were the three major causes. There was a substantial year after year increase in mortality due to falls. Deaths due to motor vehicle crashes and drowning were more common in summer months, and deaths caused by falls and burns were more common in winter months.
Conclusion
The share of unintentional injury among all-cause mortality and the mortality from falls increased in Canada during the period 2001 to 2007.
Collapse
Affiliation(s)
- Y Chen
- Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - F Mo
- Consumer Product Safety and Injury Risk Assessment Program Working Group, Science Integration Division, Centre for Chronic Disease Prevention and Control, Public Health Agency of Canada Ottawa, Ontario, Canada
| | - QL Yi
- Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Y Jiang
- Consumer Product Safety and Injury Risk Assessment Program Working Group, Science Integration Division, Centre for Chronic Disease Prevention and Control, Public Health Agency of Canada Ottawa, Ontario, Canada
| | - Y Mao
- Consumer Product Safety and Injury Risk Assessment Program Working Group, Science Integration Division, Centre for Chronic Disease Prevention and Control, Public Health Agency of Canada Ottawa, Ontario, Canada
| |
Collapse
|
47
|
Chen Y, Mo F, Yi QL, Jiang Y, Mao Y. Unintentional injury mortality and external causes in Canada from 2001 to 2007. Chronic Dis Inj Can 2013; 33:95-102. [PMID: 23470175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
INTRODUCTION To understand the distribution pattern and time trend of unintentional injury mortalities is crucial in order to develop prevention strategies. METHODS We analyzed vital statistics data from Canada (excluding Quebec) for 2001 to 2007. Mortality rates were age- and sex-standardized to the 2001 Canadian population. An autoregressive model was used for time-series analysis. RESULTS Overall mortality rate steadily decreased but unintentional injury mortality rate was stable over the study period. The three territories had the highest mortality rates. Unintentional injury deaths were less common in children than in youths/adults. After 60, the mortality rate increased steadily with age. Males were more likely to die of unintentional injury, and the male/female ratio peaked in the 25- to 29-year age group. Motor vehicle crashes, falls and poisoning were the three major causes. There was a substantial year after year increase in mortality due to falls. Deaths due to motor vehicle crashes and drowning were more common in summer months, and deaths caused by falls and burns were more common in winter months. CONCLUSION The share of unintentional injury among all-cause mortality and the mortality from falls increased in Canada during the period 2001 to 2007.
Collapse
Affiliation(s)
- Y Chen
- Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada.
| | | | | | | | | |
Collapse
|
48
|
Ma BBY, Kam MKM, Leung SF, Hui EP, King AD, Chan SL, Mo F, Loong H, Yu BKH, Ahuja A, Chan ATC. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Ann Oncol 2012; 23:1287-1292. [PMID: 21948811 DOI: 10.1093/annonc/mdr401] [Citation(s) in RCA: 95] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/06/2023] Open
Abstract
BACKGROUND Based on our previous work on the clinical activity of cetuximab in recurrent nasopharyngeal carcinoma (NPC), we evaluated the feasibility of adding cetuximab to concurrent cisplatin and intensity-modulated radiotherapy (IMRT) in locoregionally advanced NPC. PATIENTS AND METHODS Patients with American Joint Committee on Cancer stage III-IVB NPC were given an initial dose of cetuximab (400 mg/m(2)) 7-10 days before receiving concurrent IMRT, weekly cisplatin (30 mg/m(2)/week) and cetuximab (250 mg/m(2)/week). RESULTS Thirty patients (median age of 45 years) with stage III (67%), IVA (30%) and IVB (3%) nonkeratinizing NPC were enrolled. Grade 3-4 oropharyngeal mucositis occurred in 26 (87%) patients and 10 (33%) patients required short-term nasogastric feeding. Grade 3 radiotherapy-related dermatitis occurred in six patients (20%) and three patients (10%) had grade 3 cetuximab-related acneiform rash. These grade 3-4 skin and mucosal toxic effects were manageable and reversible. At a median follow-up of 31.8 months [95% confidence interval (CI) 26.2-32.1 months], the 2-year progression-free survival was 86.5% (95% CI 74.3% to 98.8%). CONCLUSIONS Concurrent administration of cetuximab, weekly cisplatin and IMRT is a feasible strategy against locoregionally advanced NPC. Preliminary survival data compare favorably with historic data and further follow-up is warranted.
Collapse
Affiliation(s)
- B B Y Ma
- State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute. The Chinese University of Hong Kong.
| | - M K M Kam
- State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute. The Chinese University of Hong Kong
| | - S F Leung
- State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute. The Chinese University of Hong Kong
| | - E P Hui
- State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute. The Chinese University of Hong Kong
| | - A D King
- Imaging and Interventional Radiology, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China
| | - S L Chan
- State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute. The Chinese University of Hong Kong
| | - F Mo
- State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute. The Chinese University of Hong Kong
| | - H Loong
- State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute. The Chinese University of Hong Kong
| | - B K H Yu
- State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute. The Chinese University of Hong Kong
| | - A Ahuja
- Imaging and Interventional Radiology, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China
| | - A T C Chan
- State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute. The Chinese University of Hong Kong
| |
Collapse
|
49
|
Mo F, Chernyshov D, Mathiesen RH, Breiby DW, Tybell T. Hysteresis effects of weak Efields on the domain structure in thin PbTiO 3films. Acta Crystallogr A 2011. [DOI: 10.1107/s0108767311091513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
50
|
Hui E, Ma B, King A, Mo F, Chan S, Kam M, Loong H, Ahuja A, Zee B, Chan A. Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. Ann Oncol 2011; 22:1280-1287. [DOI: 10.1093/annonc/mdq629] [Citation(s) in RCA: 89] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
|